Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

The agency announced it is taking steps to increase competition within the prescription drug market.


FDA Acts to Improve Market Competition

Takeda inaugurated expanded capacity of solid-dosage drugs at its site in Oranienburg, Germany.

Takeda Finishes Construction of Manufacturing Facility in Germany

The European Medicines Agency approved Prezista (darunavir) made via a continuous manufacturing process at Janssen's facility in Puerto Rico.

EMA Approves Janssen Drug Made Via Continuous Manufacturing

The agency recommended approval of treatments for hepatitis C, cancer, multiple sclerosis, and arthritis.


EMA Recommends Approval for Eight New Drugs, One Biosimilar

A loan from the European Investment Bank will give BiondVax resources for Phase III trials and a manufacturing facility for its universal flu vaccine.


BiondVax Receives European Union Investment in Universal Flu Vaccine Development

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

The need for flexibility and higher quality are driving advances in parenteral manufacturing and fill/finish equipment. 

Looking at Trends in Parenteral Manufacturing

FDA Commissioner Scott Gottlieb announced the agency will hold a public meeting on drug competition as part of its Drug Competition Action Plan. 


FDA Announces Public Meeting on Generic Drugs

The European Commission approved Rixathon for use in all indications of its reference medicine, MabThera. 


Sandoz Scores European Approval for Biosimilar Rituximab

Aptar now manufactures its child-resistant pump, designed to meet US CPC requirements, at its facility in Congers, New York. 

Aptar Adds Nasal Pump Manufacturing Capacity

At an industry seminar hosted by Leistritz Extrusion, experts explained the use of extrusion equipment to mix polymeric excipients with APIs for solubility enhancement and for multifunctional and specialty dosage forms, including implants. 
